AOD-9604: Trial History, Compounding Status & Sport Ban

Common contexts

• Clinics may reference this peptide within broader wellness or longevity pathways.
• Use this directory page to compare profile transparency and consultation options.

Safety information

• This directory is informational and does not provide medical advice.
• Always discuss suitability and risk profile directly with a licensed clinician.

Clear intro

AOD-9604 is the rare peptide whose problem isn't missing evidence but unflattering evidence: real trials, real safety data, and an efficacy result that ended its development. Honest pages lead with that.

Who this is for

This page is for people comparing fat-loss peptides who want the actual trial history, and for athletes who need to know its WADA status despite its benign reputation.

What to ask before choosing a clinic

• The Phase 2 trials found insufficient efficacy for weight loss — what effect are you expecting for me, based on what?
• How does this compare with approved weight-management options with far stronger evidence?
• Is your supply from a licensed compounding pharmacy?

Pricing and red flags

Compare against approved weight-management options first — the evidence gap between AOD-9604 and modern approved medicines is very large, and pricing should be read in that light.

• Marketing it as a proven fat-loss peptide without mentioning the failed efficacy endpoint.
• No WADA warning for athletic clients.
• Research-chemical sourcing when licensed compounding is available.

What is AOD-9604?

AOD-9604 ('anti-obesity drug 9604') is a modified fragment of the human growth hormone molecule — the 176–191 region associated with lipolytic activity — designed to influence fat metabolism without growth hormone's growth-promoting effects. Developed by an Australian company, it went further down the clinical pathway than almost any other peptide clinics now sell: Phase 2 trials enrolling over 300 obese patients. Those trials found it well tolerated but insufficiently effective, and development as an obesity medicine stopped. It has never been approved by any major regulator, but in the US it occupies an unusual position: withdrawn from the FDA's restricted compounding nomination and left unrestricted by the 2024–2026 reclassifications, keeping it accessible through compounding pharmacies.

How it works

AOD-9604 mimics the region of growth hormone thought to drive fat breakdown, without binding the growth hormone receptor — the design goal was fat loss without growth effects or blood-sugar disruption. The clinical record shows the design partly worked: trials reported a benign safety profile, but the weight-loss effect was too small to justify approval. That is worth sitting with — the best-studied 'fat-loss peptide' on clinic menus is one whose fat-loss effect was formally judged insufficient.

Cost overview

In the US it is one of the few clinic peptides legitimately available through compounding pharmacies, so pricing varies with pharmacy and programme. The evidence questions — what effect size, for what goal — matter more than the monthly figure. See the peptide therapy cost guide.

What to expect from clinics

• A credible provider should know — and share — that Phase 2 trials found insufficient efficacy for obesity.
• Expect clarity that it is WADA-banned despite its mild reputation.
• In the US, expect sourcing from a licensed compounding pharmacy rather than research-chemical vendors.

Safety considerations

AOD-9604 has more human safety data than most clinic peptides — trials in hundreds of patients reported good tolerability — but that same programme found insufficient efficacy for obesity, and long-term data outside trials is limited. It is prohibited in sport at all times. Anyone considering it should weigh it against approved options with stronger evidence, with a licensed clinician. This page does not recommend AOD-9604 and does not provide dosing or administration guidance.

Compare this with semaglutide vs tirzepatide or move into city pages such as Los Angeles and New York if you want to compare how providers frame these treatments locally.